TP53 and endometrial cancer: Another double-blind RCT was conducted on 1095 patients (median age 62 years) with newly diagnosed FIGO stage I/II endometrial cancer with non-endometrial or endometrial histology with TP53 abnormality or stage III or IVA with any histology [40].